Age-Specific Signatures of Glioblastoma at the Genomic, Genetic, and Epigenetic Levels

Age is a powerful predictor of survival in glioblastoma multiforme (GBM) yet the biological basis for the difference in clinical outcome is mostly unknown. Discovering genes and pathways that would explain age-specific survival difference could generate opportunities for novel therapeutics for GBM. Here we have integrated gene expression, exon expression, microRNA expression, copy number alteration, SNP, whole exome sequence, and DNA methylation data sets of a cohort of GBM patients in The Cancer Genome Atlas (TCGA) project to discover age-specific signatures at the transcriptional, genetic, and epigenetic levels and validated our findings on the REMBRANDT data set. We found major age-specific signatures at all levels including age-specific hypermethylation in polycomb group protein target genes and the upregulation of angiogenesis-related genes in older GBMs. These age-specific differences in GBM, which are independent of molecular subtypes, may in part explain the preferential effects of anti-angiogenic agents in older GBM and pave the way to a better understanding of the unique biology and clinical behavior of older versus younger GBMs.

[1]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[2]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[3]  Norbert Gretz,et al.  miRWalk - Database: Prediction of possible miRNA binding sites by "walking" the genes of three genomes , 2011, J. Biomed. Informatics.

[4]  Kevin Gaston,et al.  PRH/Hhex Controls Cell Survival through Coordinate Transcriptional Regulation of Vascular Endothelial Growth Factor Signaling , 2010, Molecular and Cellular Biology.

[5]  D. Botstein,et al.  Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[6]  R. Lempicki,et al.  Evaluation of gene expression measurements from commercial microarray platforms. , 2003, Nucleic acids research.

[7]  S. Nelson,et al.  Bevacizumab and chemotherapy for recurrent glioblastoma , 2009, Neurology.

[8]  John L Cleveland,et al.  c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. , 2002, Genes & development.

[9]  L. Stewart,et al.  Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials , 2002, The Lancet.

[10]  John A Butman,et al.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Tracy T Batchelor,et al.  Angiogenesis as a therapeutic target in malignant gliomas. , 2009, The oncologist.

[12]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[13]  Santosh Kesari,et al.  Understanding glioblastoma tumor biology: the potential to improve current diagnosis and treatments. , 2011, Seminars in oncology.

[14]  Yuan Qi,et al.  Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA , IDH 1 , EGFR , and NF 1 Citation Verhaak , 2010 .

[15]  D. Nelson,et al.  Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. , 1993, International journal of radiation oncology, biology, physics.

[16]  Richard G Grundy,et al.  Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  N. Ahuja,et al.  Aging, methylation and cancer. , 2000, Histology and histopathology.

[18]  Yuri Kotliarov,et al.  High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances. , 2006, Cancer research.

[19]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[20]  Daniel J. Brat,et al.  Genetic and hypoxic regulation of angiogenesis in gliomas , 2004, Journal of Neuro-Oncology.

[21]  Santiago Lamas,et al.  The non-canonical NOTCH ligand DLK1 exhibits a novel vascular role as a strong inhibitor of angiogenesis. , 2012, Cardiovascular research.

[22]  Paul S Mischel,et al.  Identification of molecular subtypes of glioblastoma by gene expression profiling , 2003, Oncogene.

[23]  Jean-Yves Delattre,et al.  Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. , 2011, Neuro-oncology.

[24]  M. W. Linn,et al.  Psychological correlates of survival in nursing home cancer patients. , 1989, The Gerontologist.

[25]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[26]  S. Horvath,et al.  Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age , 2008, BMC Medical Genomics.

[27]  P. Kleihues,et al.  Epidemiology and etiology of gliomas , 2005, Acta Neuropathologica.

[28]  Jing Chen,et al.  Restraint of angiogenesis by zinc finger transcription factor CTCF-dependent chromatin insulation , 2011, Proceedings of the National Academy of Sciences.

[29]  T. Golub,et al.  Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. , 2003, Cancer research.

[30]  David J. Arenillas,et al.  JASPAR 2010: the greatly expanded open-access database of transcription factor binding profiles , 2009, Nucleic Acids Res..

[31]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[32]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[33]  D. Bigner,et al.  Glioblastoma multiforme: a review of where we have been and where we are going , 2009, Expert opinion on investigational drugs.

[34]  E. Domany,et al.  Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Elizabeth Eisenhauer,et al.  Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. , 2008, The Lancet. Oncology.

[36]  Wolfgang Wagner,et al.  Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. , 2010, Genome research.

[37]  Dong Soon Choi,et al.  Antiangiogenic antitumor activities of IGFBP-3 are mediated by IGF-independent suppression of Erk1/2 activation and Egr-1-mediated transcriptional events. , 2011, Blood.

[38]  Mark R Cookson,et al.  Distinct DNA methylation changes highly correlated with chronological age in the human brain. , 2011, Human molecular genetics.

[39]  S. Baylin,et al.  Aging and DNA methylation in colorectal mucosa and cancer. , 1998, Cancer research.

[40]  Frédéric Dayan,et al.  The HIF-1-inducible lysyl oxidase activates HIF-1 via the Akt pathway in a positive regulation loop and synergizes with HIF-1 in promoting tumor cell growth. , 2011, Cancer research.

[41]  R. Prentice,et al.  Commentary on Andersen and Gill's "Cox's Regression Model for Counting Processes: A Large Sample Study" , 1982 .

[42]  M. Katoh,et al.  WNT/PCP signaling pathway and human cancer (review). , 2005, Oncology reports.

[43]  Gerben Menschaert,et al.  PubMeth: a cancer methylation database combining text-mining and expert annotation , 2007, Nucleic Acids Res..

[44]  Manel Esteller,et al.  Epigenetics and aging: the targets and the marks. , 2007, Trends in genetics : TIG.

[45]  Jing Chen,et al.  Sp1 inhibition-mediated upregulation of VEGF165b induced by rh-endostatin enhances antiangiogenic and anticancer effect of rh-endostatin in A549 , 2011, Tumor Biology.

[46]  Pedro Martínez,et al.  Identification of novel candidate target genes in amplicons of Glioblastoma multiforme tumors detected by expression and CGH microarray profiling , 2006, Molecular Cancer.

[47]  Pengyuan Yang,et al.  NDRG2 induced by oxidized LDL in macrophages antagonizes growth factor productions via selectively inhibiting ERK activation. , 2010, Biochimica et biophysica acta.

[48]  Paul S Mischel,et al.  Gene expression profiling identifies molecular subtypes of gliomas , 2003, Oncogene.

[49]  C. Bokemeyer,et al.  Tolerance to chemotherapy in elderly patients with cancer. , 2007, Cancer control : journal of the Moffitt Cancer Center.

[50]  R. Gill,et al.  Cox's regression model for counting processes: a large sample study : (preprint) , 1982 .

[51]  Allan H. Friedman,et al.  A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain , 1996 .

[52]  Graziano Pesole,et al.  Pscan: finding over-represented transcription factor binding site motifs in sequences from co-regulated or co-expressed genes , 2009, Nucleic Acids Res..

[53]  Koji Yoshimoto,et al.  Distinct transcription profiles of primary and secondary glioblastoma subgroups. , 2006, Cancer research.

[54]  Luigi Ferrucci,et al.  Abundant Quantitative Trait Loci Exist for DNA Methylation and Gene Expression in Human Brain , 2010, PLoS genetics.

[55]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[56]  D. Chung,et al.  N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma , 2008, Oncogene.

[57]  E C Halperin,et al.  A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. CNS Cancer Consortium. , 1996, International journal of radiation oncology, biology, physics.

[58]  John Garland,et al.  ALK1 signalling analysis identifies angiogenesis related genes and reveals disparity between TGF-β and constitutively active receptor induced gene expression , 2006, BMC cardiovascular disorders.

[59]  E. Shtivelman,et al.  Metastasis suppressor CC3 inhibits angiogenic properties of tumor cells in vitro , 2001, Oncogene.

[60]  Jan C Buckner,et al.  Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  Ting-ting Wang,et al.  Stanniocalcin-1 promotes tumor angiogenesis through up-regulation of VEGF in gastric cancer cells , 2011, Journal of Biomedical Science.

[62]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[63]  Yuri Kotliarov,et al.  Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. , 2009, Cancer research.

[64]  Claudio R. Santos,et al.  Vaccinia-Related Kinase 2 Modulates the Stress Response to Hypoxia Mediated by TAK1 , 2007, Molecular and Cellular Biology.

[65]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .